Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Tongue Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prolactinoma 1Pleural Effusion, Malignant 1Pituitary Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Growth Hormone-Secreting Pituitary Adenoma 1Fatigue 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenoma, Chromophobe 1Adenoma, Basophil 1Adenoma, Acidophil 1

Interventions

Temozolomide 1Microarray Analysis 1DNA Methylation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Adenoma, Chromophobe × Microarray Analysis × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡